全文获取类型
收费全文 | 130578篇 |
免费 | 41733篇 |
国内免费 | 316篇 |
专业分类
耳鼻咽喉 | 1849篇 |
儿科学 | 5422篇 |
妇产科学 | 688篇 |
基础医学 | 28148篇 |
口腔科学 | 7216篇 |
临床医学 | 14893篇 |
内科学 | 29099篇 |
皮肤病学 | 4551篇 |
神经病学 | 19614篇 |
特种医学 | 6038篇 |
外国民族医学 | 5篇 |
外科学 | 16214篇 |
综合类 | 885篇 |
现状与发展 | 4篇 |
一般理论 | 8篇 |
预防医学 | 8464篇 |
眼科学 | 1474篇 |
药学 | 12517篇 |
中国医学 | 2031篇 |
肿瘤学 | 13507篇 |
出版年
2023年 | 191篇 |
2022年 | 403篇 |
2021年 | 1983篇 |
2020年 | 6345篇 |
2019年 | 11797篇 |
2018年 | 11362篇 |
2017年 | 12524篇 |
2016年 | 11643篇 |
2015年 | 11577篇 |
2014年 | 11684篇 |
2013年 | 12356篇 |
2012年 | 10887篇 |
2011年 | 10933篇 |
2010年 | 9466篇 |
2009年 | 6065篇 |
2008年 | 6718篇 |
2007年 | 5031篇 |
2006年 | 4851篇 |
2005年 | 4548篇 |
2004年 | 4401篇 |
2003年 | 4017篇 |
2002年 | 3757篇 |
2001年 | 2934篇 |
2000年 | 1749篇 |
1999年 | 670篇 |
1998年 | 452篇 |
1997年 | 368篇 |
1996年 | 373篇 |
1995年 | 362篇 |
1994年 | 334篇 |
1993年 | 285篇 |
1992年 | 278篇 |
1991年 | 228篇 |
1990年 | 212篇 |
1989年 | 168篇 |
1988年 | 173篇 |
1987年 | 152篇 |
1986年 | 148篇 |
1985年 | 200篇 |
1984年 | 197篇 |
1983年 | 153篇 |
1982年 | 123篇 |
1981年 | 126篇 |
1980年 | 94篇 |
1979年 | 71篇 |
1978年 | 52篇 |
1977年 | 34篇 |
1976年 | 26篇 |
1974年 | 34篇 |
1973年 | 26篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
61.
62.
S. Bereswill F. Fassbinder C. Völzing A. Covacci R. Haas M. Kist 《Medical microbiology and immunology》1998,186(4):177-187
Various strains of Helicobacter pylori were able to lyse erythrocytes from sheep, horse, and human when grown on blood agar. The hemolysis did not depend on the
production of the vacuolating cytotoxin VacA as demonstrated by the hemolytic behavior of an isogenic vacA-negative mutant strain. The hemolytic activity could be detected in cell-free supernatants and was not regulated by iron.
To isolate genes coding for proteins involved in the destruction of erythrocytes, a plasmid-based DNA library was screened
for expression of lytic activity on blood agar. This approach revealed that the H. pylori ribA gene confers hemolytic properties to Escherichia coli. The ribA gene encodes the enzyme GTP-cyclohydrolase II [EC 3.5.4.25] that catalyzes the initial step in the synthesis of riboflavin.
The predicted amino acid sequence of the H. pylori RibA protein showed a high degree of similarity to equivalent enzymes from microorganisms and from plants. The single gene
on a plasmid restored riboflavin synthesis in a ribA mutant of E. coli and induced hemolytic activity. Furthermore, ribA overexpression was associated with the production of a fluorescent yellow molecule that was not identical with riboflavin.
Hemolysis was also seen for the ribA gene from E. coli, indicating that this feature was not specific for the H. pylori gene. The presence of ribA in various H. pylori strains was confirmed by Southern blot hybridization and by polymerase chain reaction with specific primers. This analysis
revealed that microdiversity exists within the DNA region upstream from ribA, which was further confirmed by nucleotide sequence analysis.
Received: 25 July 1997 相似文献
63.
64.
汕头卫生检疫局空港处对汕头航空口岸—宗入境二级货包的监测过程及对有关运输工作人员作了放射知识问卷调查。从中发现。运输单位货物存放设施落后。有关工作人员放射卫生知识欠缺,对放射污染可能造成的危害缺乏正确的认识。为此,笔者提出了自己的看法,以期对放射监测工作的进一步完善提供参考。 相似文献
65.
PROBLEM: There is substantial data that support the efficacy of paternal leukocyte immunization (PLI) for the treatment of alloimmune mediated miscarriage; however, there is confusion regarding the laboratory test that should be performed to determine levels of maternal anti-paternal leukocyte antibodies (MAPLA). METHOD: Popular methodologies employed include: 1) microcytotoxicity (MCX), 2) mixed lymphocyte culture (MLC), and 3) cell flow cytometry crossmatch (FCXM). Cell flow cytometry crossmatch correlates well with the more difficult MLC assay although the former proves the more sensitive study. This work compares the MCX assays with FCXM. The study group consisted of ten women who had a history of three or more spontaneous abortions (SABs). All ten had very low levels (<10%) of MAPLA as measured by FCXM. Following PLI all subjects demonstrated elevated levels (>50%) of MAPLA by FCXM. At 12 weeks gestation, sera were simultaneously measured for MAPLA by MCX and FCXM. RESULTS: Although all ten patients had very high levels of MAPLA by FCXM during pregnancy, five of ten had antibodies to HLA Class I and two of ten had antibodies to HLA Class II paternal antigens by MCX. Furthermore, all patients who were positive by MCX to paternal Class I antigens were also positive to Class I antigens not seen in either parent. Both patients who were positive by MCX to paternal Class II antigens were also positive to maternal Class II antigens. Notable is that all ten women eventually delivered healthy infants. CONCLUSION: Based on this preliminary study, the MCX assay is neither sensitive or reliable enough to determine the need and/or to monitor the effectiveness of PLI. Flow cytometry should be the modality of choice when determining the need for alloimmunotherapy and to monitor the effectiveness of treatment. 相似文献
66.
K. A. Rolls P. A. Phillips K. Aldred K. J. Hardy 《Clinical and experimental pharmacology & physiology》1994,21(3):227-230
1. Since plasma renin activity is increased in cyclosporin A (CsA)-induced hypertension in the rat, the role of the vascular renin-angiotensin system (RAS) in CsA-induced hypertension was investigated in rat mesenteric resistance vessels. 2. Female Wistar rats received CsA (10 mg/kg per day, s.c.) or vehicle for 30 days. CsA treatment increased tail-cuff systolic blood pressure (CsA treated 135 ± 3 mmHg vs control 125 ± 1 mmHg, P<0.0001). 3. Mesenteric resistance arteries (200–300 μm) were isolated and mounted in a microvessel myograph. Concentration-response curves to tetradecapeptide renin substrate (10-11-10?6 mol/L), angiotensin I (10-l1-10?6 mol/L) and angiotensin II (10-12-10?6 mol/L) showed no differences between CsA-treated and control groups. 4. Mesenteric vascular angiotensin-converting enzyme (ACE) characteristics were determined by radioligand binding. There were no differences in the content or affinity of ACE between CsA-treated and control rats. 5. These results suggest that the mesenteric vascular RAS does not play a major role in CsA-induced hypertension in the rat. 相似文献
67.
68.
Enza-Maria Valente Anjum Misbahuddin Francesco Brancati Mark R Placzek Barbara Garavaglia Sergio Salvi Andrea Nemeth Charles Shaw-Smith Nardo Nardocci Anna-Rita Bentivoglio Alfredo Berardelli Roberto Eleopra Bruno Dallapiccola Thomas T Warner 《Movement disorders》2003,18(9):1047-1051
The epsilon-sarcoglycan gene (SGCE) on human chromosome 7q21 has been reported to be a major locus for inherited myoclonus-dystonia. Linkage to the SGCE locus has been detected in the majority of families tested, and mutations in the coding region have been found recently in families with autosomal dominant myoclonus-dystonia. To evaluate the relevance of SGCE in myoclonus-dystonia, we sequenced the entire coding region of the epsilon-sarcoglycan gene in 16 patients with either sporadic or familial myoclonus-dystonia. No mutations were found. This study suggests that epsilon-sarcoglycan does not play an important role in sporadic myoclonus-dystonia and supports genetic heterogeneity in familial cases. 相似文献
69.
Ligia Teban Hubert Pehamberger Klaus Wolff Michael Binder Harald Kittler 《Journal der Deutschen Dermatologischen Gesellschaft》2003,1(4):292-296
Background and objectives: The aim of this study was to evaluate the practical value of the dermatoscopic classification of Clark nevi Patients and methods: Dermatoscopic images of 268 lesions clinically and dermatoscopically diagnosed as Clark nevi were presented to 2 dermatologists without knowledge of the histological diagnosis. The dermatologists evaluated the lesions according to a simplified version of the classification scheme for Clark nevi proposed by Hofmann‐Wellenhof and differentiated between 12 different types of Clark nevi. Results: The most common type of Clark nevus was the reticular‐homogenous type (n = 64, 23,9 %), followed by the globular‐homogeneous type (n = 32, 12 %) and by the homogenous type (n = 30, 11,2 %). The overall inter‐rater agreement between the examiners was moderate to good (kappa = 0,58). The highest level of agreement was found for the peripheral hyperpigmented type (kappa = 0,83). Histologically, 17 lesions (6,3 %) were diagnosed as melanomas. The frequency of melanoma was highest among the peripheral‐hyperpigmented type for one observer and among the homogenous type for the other observer. No melanoma was found among the globular, reticular‐globular, and the central‐hyperpigmented types. Conclusions: A dermatoscopic classification of Clark nevi is practically feasible and allows – to some extent – a risk stratification of Clark nevi, which could be useful for clinical management. 相似文献
70.
Marc Ziegler Alexandre Castro-Caldas Susanna Del Signore Olivier Rascol 《Movement disorders》2003,18(4):418-425
Piribedil is a non-ergot D2/D3 agonist with a significant antagonist action on alpha2A and alpha2C adrenergic receptor subtypes. This double-blind placebo-controlled study was undertaken to confirm the efficacy of 150 mg/day piribedil po in improving motor symptoms of idiopathic Parkinson's disease (PD) in nonfluctuating patients insufficiently controlled by a stable daily dose of levodopa (L-dopa). Efficacy was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) III score as primary criterion over 4 months. A second comparison was planned at 6 months, after possible adjustment of L-dopa. At 4 months, the rate of response, defined as a 30% decrease from baseline on UPDRS III score, was significantly greater with piribedil compared with placebo (56.4% vs. 37.7%; P = 0.040). At 6 months, the better efficacy of piribedil was maintained (61.8% of responders vs. 39.6% on placebo; P = 0.020). The difference between groups on UPDRS III change from baseline reached statistical significance only at 6 months: -10.0 points in the piribedil group vs. -6.7 points in the placebo group (P = 0.037). Secondary end-points were not significantly different. The most frequently reported adverse events were gastrointestinal symptoms (27 of 61 patients in the piribedil group vs. 13 of 54 patients in the placebo group). In conclusion, a 6-month oral administration of 150 mg/day piribedil in combination with L-dopa is well tolerated, except for minor gastrointestinal symptoms at the beginning of the treatment and significantly improves motor symptoms compared with placebo in PD nonfluctuating patients. 相似文献